- Home
- ATYR vs TNGX Comparison
ATYR vs TNGX Comparison
Compare ATYR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- TNGX
- Stock Information
- Founded
- ATYR 2005
- TNGX 2014
- Country
- ATYR United States
- TNGX United States
- Employees
- ATYR N/A
- TNGX N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- TNGX Health Care
- Exchange
- ATYR Nasdaq
- TNGX Nasdaq
- Market Cap
- ATYR 451.3M
- TNGX 351.2M
- IPO Year
- ATYR 2015
- TNGX N/A
- Fundamental
- Price
- ATYR $5.30
- TNGX $6.01
- Analyst Decision
- ATYR Strong Buy
- TNGX Strong Buy
- Analyst Count
- ATYR 6
- TNGX 6
- Target Price
- ATYR $20.20
- TNGX $12.20
- AVG Volume (30 Days)
- ATYR 3.7M
- TNGX 2.7M
- Earning Date
- ATYR 08-12-2025
- TNGX 08-06-2025
- Dividend Yield
- ATYR N/A
- TNGX N/A
- EPS Growth
- ATYR N/A
- TNGX N/A
- EPS
- ATYR N/A
- TNGX N/A
- Revenue
- ATYR N/A
- TNGX $40,990,000.00
- Revenue This Year
- ATYR $960.85
- TNGX N/A
- Revenue Next Year
- ATYR $1,283.47
- TNGX N/A
- P/E Ratio
- ATYR N/A
- TNGX N/A
- Revenue Growth
- ATYR N/A
- TNGX 10.09
- 52 Week Low
- ATYR $1.58
- TNGX $1.03
- 52 Week High
- ATYR $5.98
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ATYR 56.28
- TNGX 76.36
- Support Level
- ATYR $5.07
- TNGX $5.34
- Resistance Level
- ATYR $5.58
- TNGX $6.40
- Average True Range (ATR)
- ATYR 0.39
- TNGX 0.50
- MACD
- ATYR -0.04
- TNGX -0.02
- Stochastic Oscillator
- ATYR 64.20
- TNGX 84.08
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.